In the past decade, nucleic-acid-based drugs have become firmly established as a therapeutic modality. Drugs in two classes have now reached the market for multiple diseases—antisense oligonucleotides ...

The development of nucleic-acid therapeutics, ranging from aptamers and antisense RNA to messenger RNA (mRNA)-based vaccines and gene therapies, is a rapidly evolving industry that has the potential ...

DNA is the poster child for high-specificity binding. As long as their base sequences match, two complementary strands of DNA can navigate through a sea of biomolecules, find each other, and hold fast ...

Harnessing surface engineering strategies to functionalize nucleic acid-lipid nanoparticles (LNPs) for improved performance has been a hot research topic since the approval of the first siRNA drug, ...

BOSTON--(BUSINESS WIRE)--Alloy Therapeutics, a biotechnology ecosystem company, announced the launch of its novel AntiClastic™ Antisense Oligonucleotide (AntiClastic ASO) platform, which employs ...

As the global small nucleic acid drugs market rapidly expands, driven by growing demand for precise treatments targeting genetic disorders, rare diseases, and cancer. The high specificity of small ...

Anti-nucleolin DNA aptamer, iSN04, inhibits angiogenesis. Mouse aortic rings embedded in collagen gel were cultured with or without 30 µM iSN04 for 6 days. Neovascular sprouting, a model of ...

Developing high-quality, safe, and effective drugs is a complex process that requires varied scientific skills and stringent regulatory assessments. Drug development is a process that spans many years ...

BEDMINSTER, N.J., Jan. 30, 2023 (GLOBE NEWSWIRE) -- Matinas BioPharma (MTNB) (NYSE AMER: MTNB, Matinas), a clinical-stage biopharmaceutical company focused on redefining the intracellular delivery of ...

Ribonucleic acid, or RNA, has emerged as a hot new field after mRNA and miRNA discoveries won Nobel Prizes in 2023 and 2024, respectively, drawing attention to its scientific value and industrial ...

The rapid advancement of artificial intelligence (AI) is transforming the field of structural biology. In May 2024, DeepMind and Isomorphic Labs launched AlphaFold 3 (AF3), a revolutionary AI system ...